Elevated serum cystatin C level is an independent predictor of contrast-induced nephropathy and adverse outcomes in patients with peripheral artery disease undergoing endovascular therapy

Gwang Sil Kim, Young Guk Ko, Dong Ho Shin, Jung Sun Kim, Byeong Keuk Kim, Donghoon Choi, Myeongki Hong, Yangsoo Jang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: The aim of this study was to investigate the association of serum cystatin C levels with contrast-induced nephropathy (CIN) and adverse clinical events in patients with peripheral artery disease (PAD). Methods: A total of 240 PAD patients who received endovascular therapy were included in this retrospective analysis. Serial serum levels of creatinine and cystatin C before and within 48 hours of endovascular therapy were evaluated for the incidence of CIN. The relationship between serum cystatin C levels and the incidence of major adverse events, defined as a composite of all-cause death, myocardial infarction, stroke, amputation, and target vessel revascularization, was investigated. Results The incidence of CIN increased from 1.7% to 27.9%, depending on the quartile of baseline cystatin C level. Baseline serum cystatin C level (area under the curve of the receiver operating characteristic curve, 0.757; 95% confidence interval [CI], 0.696-0.735) predicted the incidence of CIN better than baseline serum creatinine level (area under the curve, 0.629; 95% CI, 0.563-0.691; P <.001). An elevated baseline cystatin C level was an independent predictor of CIN (hazard ratio, 14.37; 95% CI, 4.11-50.19; P <.001) and major adverse events in patients with PAD (hazard ratio, 2.57; 95% CI, 1.28-5.17; P =.008). Conclusions We found elevated baseline cystatin C level to be an independent risk factor for CIN and a predictor of all-cause mortality and major adverse events in patients with PAD undergoing endovascular therapy.

Original languageEnglish
Pages (from-to)1223-1230
Number of pages8
JournalJournal of Vascular Surgery
Volume61
Issue number5
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Cystatin C
Peripheral Arterial Disease
Serum
Confidence Intervals
Incidence
Therapeutics
Area Under Curve
Creatinine
Amputation
ROC Curve
Cause of Death
Stroke
Myocardial Infarction
Mortality

All Science Journal Classification (ASJC) codes

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

@article{ba7163b5f3e44f5d856e57d9bad23066,
title = "Elevated serum cystatin C level is an independent predictor of contrast-induced nephropathy and adverse outcomes in patients with peripheral artery disease undergoing endovascular therapy",
abstract = "Objective: The aim of this study was to investigate the association of serum cystatin C levels with contrast-induced nephropathy (CIN) and adverse clinical events in patients with peripheral artery disease (PAD). Methods: A total of 240 PAD patients who received endovascular therapy were included in this retrospective analysis. Serial serum levels of creatinine and cystatin C before and within 48 hours of endovascular therapy were evaluated for the incidence of CIN. The relationship between serum cystatin C levels and the incidence of major adverse events, defined as a composite of all-cause death, myocardial infarction, stroke, amputation, and target vessel revascularization, was investigated. Results The incidence of CIN increased from 1.7{\%} to 27.9{\%}, depending on the quartile of baseline cystatin C level. Baseline serum cystatin C level (area under the curve of the receiver operating characteristic curve, 0.757; 95{\%} confidence interval [CI], 0.696-0.735) predicted the incidence of CIN better than baseline serum creatinine level (area under the curve, 0.629; 95{\%} CI, 0.563-0.691; P <.001). An elevated baseline cystatin C level was an independent predictor of CIN (hazard ratio, 14.37; 95{\%} CI, 4.11-50.19; P <.001) and major adverse events in patients with PAD (hazard ratio, 2.57; 95{\%} CI, 1.28-5.17; P =.008). Conclusions We found elevated baseline cystatin C level to be an independent risk factor for CIN and a predictor of all-cause mortality and major adverse events in patients with PAD undergoing endovascular therapy.",
author = "Kim, {Gwang Sil} and Ko, {Young Guk} and Shin, {Dong Ho} and Kim, {Jung Sun} and Kim, {Byeong Keuk} and Donghoon Choi and Myeongki Hong and Yangsoo Jang",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.jvs.2014.11.079",
language = "English",
volume = "61",
pages = "1223--1230",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "5",

}

Elevated serum cystatin C level is an independent predictor of contrast-induced nephropathy and adverse outcomes in patients with peripheral artery disease undergoing endovascular therapy. / Kim, Gwang Sil; Ko, Young Guk; Shin, Dong Ho; Kim, Jung Sun; Kim, Byeong Keuk; Choi, Donghoon; Hong, Myeongki; Jang, Yangsoo.

In: Journal of Vascular Surgery, Vol. 61, No. 5, 01.05.2015, p. 1223-1230.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Elevated serum cystatin C level is an independent predictor of contrast-induced nephropathy and adverse outcomes in patients with peripheral artery disease undergoing endovascular therapy

AU - Kim, Gwang Sil

AU - Ko, Young Guk

AU - Shin, Dong Ho

AU - Kim, Jung Sun

AU - Kim, Byeong Keuk

AU - Choi, Donghoon

AU - Hong, Myeongki

AU - Jang, Yangsoo

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Objective: The aim of this study was to investigate the association of serum cystatin C levels with contrast-induced nephropathy (CIN) and adverse clinical events in patients with peripheral artery disease (PAD). Methods: A total of 240 PAD patients who received endovascular therapy were included in this retrospective analysis. Serial serum levels of creatinine and cystatin C before and within 48 hours of endovascular therapy were evaluated for the incidence of CIN. The relationship between serum cystatin C levels and the incidence of major adverse events, defined as a composite of all-cause death, myocardial infarction, stroke, amputation, and target vessel revascularization, was investigated. Results The incidence of CIN increased from 1.7% to 27.9%, depending on the quartile of baseline cystatin C level. Baseline serum cystatin C level (area under the curve of the receiver operating characteristic curve, 0.757; 95% confidence interval [CI], 0.696-0.735) predicted the incidence of CIN better than baseline serum creatinine level (area under the curve, 0.629; 95% CI, 0.563-0.691; P <.001). An elevated baseline cystatin C level was an independent predictor of CIN (hazard ratio, 14.37; 95% CI, 4.11-50.19; P <.001) and major adverse events in patients with PAD (hazard ratio, 2.57; 95% CI, 1.28-5.17; P =.008). Conclusions We found elevated baseline cystatin C level to be an independent risk factor for CIN and a predictor of all-cause mortality and major adverse events in patients with PAD undergoing endovascular therapy.

AB - Objective: The aim of this study was to investigate the association of serum cystatin C levels with contrast-induced nephropathy (CIN) and adverse clinical events in patients with peripheral artery disease (PAD). Methods: A total of 240 PAD patients who received endovascular therapy were included in this retrospective analysis. Serial serum levels of creatinine and cystatin C before and within 48 hours of endovascular therapy were evaluated for the incidence of CIN. The relationship between serum cystatin C levels and the incidence of major adverse events, defined as a composite of all-cause death, myocardial infarction, stroke, amputation, and target vessel revascularization, was investigated. Results The incidence of CIN increased from 1.7% to 27.9%, depending on the quartile of baseline cystatin C level. Baseline serum cystatin C level (area under the curve of the receiver operating characteristic curve, 0.757; 95% confidence interval [CI], 0.696-0.735) predicted the incidence of CIN better than baseline serum creatinine level (area under the curve, 0.629; 95% CI, 0.563-0.691; P <.001). An elevated baseline cystatin C level was an independent predictor of CIN (hazard ratio, 14.37; 95% CI, 4.11-50.19; P <.001) and major adverse events in patients with PAD (hazard ratio, 2.57; 95% CI, 1.28-5.17; P =.008). Conclusions We found elevated baseline cystatin C level to be an independent risk factor for CIN and a predictor of all-cause mortality and major adverse events in patients with PAD undergoing endovascular therapy.

UR - http://www.scopus.com/inward/record.url?scp=84929029327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929029327&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2014.11.079

DO - 10.1016/j.jvs.2014.11.079

M3 - Article

VL - 61

SP - 1223

EP - 1230

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 5

ER -